Briefly, our study elucidated the expression patterns of Eph receptors and EFN ligands pan-cancer, and identified a novel biomarker of EPHB6 as a potential effective therapeutic target to improve the immunotherapy response of BLCA. The gene discussed is EPHB6; the disease is cancer.